Dr. Sang Joon Shin
Claim this profileSeverance Hospital, Yonsei University Health System
Area of expertise
Solid Tumors
Sang Joon Shin has run 5 trials for Solid Tumors. Some of their research focus areas include:
Lung Cancer
Sang Joon Shin has run 4 trials for Lung Cancer. Some of their research focus areas include:
Clinical Trials Sang Joon Shin is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting
1 award
Phase 1 & 2
10 criteria
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting
2 awards
Phase 3
More about Sang Joon Shin
Clinical Trial Related
4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Sang Joon Shin has experience with
- Pembrolizumab
- Gemcitabine
- EU101
- Docetaxel
- TTX-030
- Nab-paclitaxel
Breakdown of trials Sang Joon Shin has run
Lung Cancer
Bladder Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sang Joon Shin specialize in?
Sang Joon Shin focuses on Solid Tumors and Lung Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are EGFR negative.
Is Sang Joon Shin currently recruiting for clinical trials?
Yes, Sang Joon Shin is currently recruiting for 4 clinical trials in Seoul Other. If you're interested in participating, you should apply.
Are there any treatments that Sang Joon Shin has studied deeply?
Yes, Sang Joon Shin has studied treatments such as Pembrolizumab, Gemcitabine, EU101.
What is the best way to schedule an appointment with Sang Joon Shin?
Apply for one of the trials that Sang Joon Shin is conducting.
What is the office address of Sang Joon Shin?
The office of Sang Joon Shin is located at: Severance Hospital, Yonsei University Health System, Seoul, Other 120-752 Korea, Republic of. This is the address for their practice at the Severance Hospital, Yonsei University Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.